Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients

Sci Rep. 2017 Oct 30;7(1):14352. doi: 10.1038/s41598-017-14747-5.

Abstract

This study examines the role of M2BPGi, a novel seromarker for chronic hepatitis, in predicting hepatocellular carcinoma (HCC) among untreated chronic hepatitis B (CHB) patients. In this nested case-control study, 1070 samples were assayed for M2BPGi, including 357 samples from HCC cases, and 713 samples from non-HCC controls, collected at various times throughout follow-up. HCC case samples were stratified according to years prior to diagnosis. Associations between M2BPGi and HCC were examined with multivariate logistic regression. M2BPGi, α-fetoprotein (AFP), and hepatitis B surface antigen (HBsAg) levels were significant independent short-term predictors of HCC, while M2BPGi was insignificant in long-term analyses. Compared to M2BPGi levels <1.0 cut-off index (COI), those with levels ≥2.0 COI had multivariate odds ratios (95% CI) for HCC of 7.40 (2.40-22.78), 6.46 (2.58-16.18), and 2.24 (0.97-5.15), respectively, for prediction of HCC within 1-2, 2-5, and ≥5 years. Higher proportions of individuals had M2BPGi levels ≥2.0 COI in samples closer to HCC diagnosis. Areas under receiver operating characteristic curves for models with M2BPGi, AFP, and HBsAg levels predicting HCC within 1-2, 2-5, and >5 years were 0.84, 0.81, and 0.75. M2BPGi is a strong and independent short-term predictor of HCC in CHB patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, Neoplasm / analysis*
  • Antigens, Neoplasm / blood
  • Antiviral Agents / therapeutic use
  • Area Under Curve
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / blood
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / metabolism
  • Carrier Proteins / analysis*
  • Carrier Proteins / blood
  • Case-Control Studies
  • Female
  • Glycoproteins / analysis*
  • Glycoproteins / blood
  • Hepatitis B Surface Antigens / analysis
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / drug therapy
  • Humans
  • Liver Cirrhosis / complications
  • Liver Neoplasms / blood supply
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / metabolism
  • Male
  • Middle Aged
  • Prognosis
  • ROC Curve
  • alpha-Fetoproteins / analysis

Substances

  • Antigens, Neoplasm
  • Antiviral Agents
  • Biomarkers, Tumor
  • Carrier Proteins
  • Glycoproteins
  • Hepatitis B Surface Antigens
  • LGALS3BP protein, human
  • alpha-Fetoproteins